Berkshire Hathaway Inc. vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Berkshire Hathaway Inc. on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG is widest.

On the headline numbers, Berkshire Hathaway Inc. reports annual revenue of $371.4B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $1.05T and $327.5B. Berkshire Hathaway Inc. is headquartered in United States and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

Berkshire Hathaway Inc.: Berkshire began as a textile company and became a holding company after Warren Buffett gained control in 1965. The modern company is a collection of operating businesses and investments bound by decentralized management, conservative financing, and a long-term shareholder culture.

F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.

Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG.

Berkshire Hathaway Inc. business model: Berkshire makes money through insurance underwriting and float investment, freight rail, regulated utilities and energy infrastructure, industrial manufacturing, wholesale distribution, retail, services, and a large portfolio of equity and fixed-income investments.

F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Berkshire Hathaway Inc. stack up against those of F. Hoffmann-La Roche AG.

Berkshire Hathaway Inc. competitive advantage: Berkshire's advantage is permanent capital, insurance float, a conservative balance sheet, reputation with sellers, and a decentralized culture that attracts owner-minded managers.

F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.

Future prospects matter as much as current results. The growth strategies below explain how Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG each plan to expand from here.

Berkshire Hathaway Inc. growth strategy: Berkshire's growth strategy is not a top-down operating plan; it is disciplined capital allocation. The company reinvests in subsidiaries, buys public equities, acquires private businesses when prices fit, and keeps a fortress balance sheet for downturns.

F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.

A closer look at the financial trajectory of Berkshire Hathaway Inc. and F. Hoffmann-La Roche AG rounds out the comparison.

Berkshire Hathaway Inc.: For FY2025, Berkshire reported $371.444B in revenue and $66.968B in net income attributable to shareholders. Its filing reported about 387,800 employees worldwide at year-end. The updated net income replaces the prior-year comparison figure previously used in this profile.

F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.